<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmgenomics Pers Med</journal-id><journal-id journal-id-type="iso-abbrev">Pharmgenomics Pers Med</journal-id><journal-id journal-id-type="publisher-id">Pharmacogenomics and Personalized Medicine</journal-id><journal-title-group><journal-title>Pharmacogenomics and Personalized Medicine</journal-title></journal-title-group><issn pub-type="epub">1178-7066</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4854269</article-id><article-id pub-id-type="doi">10.2147/PGPM.S86672</article-id><article-id pub-id-type="publisher-id">pgpm-9-047</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tulsyan</surname><given-names>Sonam</given-names></name><xref ref-type="aff" rid="af1-pgpm-9-047">1</xref></contrib><contrib contrib-type="author"><name><surname>Mittal</surname><given-names>Rama Devi</given-names></name><xref ref-type="aff" rid="af2-pgpm-9-047">2</xref></contrib><contrib contrib-type="author"><name><surname>Mittal</surname><given-names>Balraj</given-names></name><xref ref-type="aff" rid="af1-pgpm-9-047">1</xref><xref ref-type="corresp" rid="c1-pgpm-9-047"/></contrib></contrib-group><aff id="af1-pgpm-9-047"><label>1</label>Department of Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India</aff><aff id="af2-pgpm-9-047"><label>2</label>Department of Urology and Renal Transplant, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India</aff><author-notes><corresp id="c1-pgpm-9-047">Correspondence: Balraj Mittal, Department of Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India, Tel +91 522 249 4322, Fax +91 522 266 8973, Email <email>bml_pgi@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2016</year></pub-date><volume>9</volume><fpage>47</fpage><lpage>58</lpage><permissions><copyright-statement>© 2016 Tulsyan et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>The ABCB1 gene encodes a permeability glycoprotein, which is one of the most extensively studied human adenosine-triphosphate (ATP)-dependent efflux transporters. </plain></SENT>
<SENT sid="2" pm="."><plain>Permeability glycoprotein is expressed in the apical membranes of tissues such as intestine, liver, blood–brain barrier, kidney, placenta, and testis and contributes to intracellular drug disposition. </plain></SENT>
<SENT sid="3" pm="."><plain>It is also highly expressed in tumor cells conferring drug resistance, which is one of the major problems in the efficacy of cancer chemotherapy treatment. ABCB1 is highly polymorphic, and three well-known single-nucleotide polymorphisms such as 1236C&gt;T, 2677G&gt;T/A, and 3435C&gt;T have been found to be associated with altered messenger RNA levels, protein folding, and drug pharmacokinetics. </plain></SENT>
<SENT sid="4" pm="."><plain>Many association studies and meta-analyses have demonstrated the clinical impact of ABCB1 polymorphisms in breast cancer treatment outcomes with respect to therapeutic response, chemotoxicity, and overall survival. </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, the aim of this review was to evaluate the effects of ABCB1 polymorphisms on the outcome of breast cancer treatment which, in future, would be important for tailoring individualized anticancer therapy. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><title>Keywords</title><kwd><italic>ABCB1</italic></kwd><kwd>P-glycoprotein</kwd><kwd>polymorphisms</kwd><kwd>breast cancer treatment</kwd><kwd>chemotherapy</kwd><kwd>response</kwd><kwd>drug resistance</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="6" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="7" pm="."><plain>Breast cancer is the most common cancer in women worldwide. </plain></SENT>
<SENT sid="8" pm="."><plain>It involves multimodal treatment that includes drugs such as anthracyclines (epirubicin/doxorubicin, adriamycin), cytotoxics (cyclophosphamide, paclitaxel, docetaxel), antiestrogens (tamoxifen), and aromatase inhibitors (exemestane, anastrozole, letrozole). </plain></SENT>
<SENT sid="9" pm="."><plain>Cytotoxic agents are the backbone of systemic treatment in chemotherapies. </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with early-staged breast cancer (stages I and II) are treated primarily with surgery followed by adjuvant chemotherapy, while patients with later-staged (stages III and IV) disease are treated with neo-adjuvant chemotherapy (NACT). </plain></SENT>
<SENT sid="11" pm="."><plain>However, such treatment is accompanied by various side effects, ranging from nausea to hair loss to myelotoxicity. </plain></SENT>
<SENT sid="12" pm="."><plain>The severity of these side effects varies from one patient to another, and it is an important problem in breast cancer therapy.1 Pharmacokinetic processes of absorption, distribution, metabolism, and excretion (ADME) play an important role in deciphering the drug treatment outcomes.2 Furthermore, genetic differences in various drug metabolizing and transporter enzymes may be responsible for interindividual variation in drug treatment outcomes3,4 and could be one of the factors for pharmacokinetic alterations. </plain></SENT>
</text></p><p><text><SENT sid="13" pm="."><plain>Adenosine triphosphate (ATP)-binding cassette (ABC) subfamily B member 1 (ABCB1) belongs to a large superfamily of primary active transporters that are present in all kingdoms of life. </plain></SENT>
<SENT sid="14" pm="."><plain>This gene is also known as multidrug resistance gene 1 (MDR1) or cluster of differentiation 243. ABCB1 gene encodes a protein known as permeability glycoprotein (P-gp), which is responsible for energy (ATP)-dependent efflux of drugs. </plain></SENT>
<SENT sid="15" pm="."><plain>It has broad substrate specificity.5 Literature on breast cancer has shown that the expression as well as genetic variations in ABCB1 is associated with altered therapeutic response.6–11 Several studies have also evaluated the effect of ABCB1 polymorphisms with chemotherapy-dependent toxicity and overall survival (OS) on patients with breast cancer.9–17 An expression study on P-gp has shown that the upregulation of this protein is a cause of multidrug resistance phenotype in anticancer therapy.18 Therefore, in order to promote effective therapeutic response, lower drug toxicity, and increased OSs, it is essential to understand the critical role of polymorphisms in ABCB1 drug transporters on the outcome of breast cancer treatments. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>In this review, we have focused on the structure, function, genetic variations present in ABCB1, and their effects on breast cancer treatment outcomes in terms of therapeutic response, survival, and drug toxicity. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="17" pm="."><plain>ABCB1 structure, function, and mode of action </plain></SENT>
</text></title><p><text><SENT sid="18" pm="."><plain>P-gp, a transmembrane-associated protein, is responsible for the exchange of molecules across the membranes by using energy from the hydrolysis of ATP.19 It belongs to one of the largest superfamilies of proteins, that is, ABC transporters.20 ABC genes are classified into seven different subfamilies – ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White (<ext-link ext-link-type="uri" xlink:href="http://nutrigene.4t.com/humanabc.htm">http://nutrigene.4t.com/humanabc.htm</ext-link>). </plain></SENT>
<SENT sid="19" pm="."><plain>In humans, P-gp is a member of the MDR/TAP subfamily and is encoded by the ABCB1 gene located on chromosome 7q21.12 (UCSC Genome Browser, March 2006 Assembly [hg18]).21,22 </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>The complete molecular structure of the gene is well known. ABCB1 was first cloned in the year 1985.23 The gene contains 28 exons and 28 introns in a genomic region of 209.6 kb (GenBank accession number NT_007933).24 Transcriptional start region consists of a proximal and distal promoter. </plain></SENT>
<SENT sid="21" pm="."><plain>Proximal promoter responsible for constitutive expression is present in exon 1 and intron 1, while distal promoter is active in patients with cancer for overexpression of the protein product. </plain></SENT>
<SENT sid="22" pm="."><plain>However, two 5′ exons are not translated. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Protein-coding sequence consists of two similar halves with approximately the same number of exons. </plain></SENT>
<SENT sid="24" pm="."><plain>However, two intron pairs within the nucleotide-binding domains (NBDs) are located at conserved positions in the two halves of the protein. </plain></SENT>
<SENT sid="25" pm="."><plain>Out of 28 introns, 26 that left disrupt the protein-coding sequence relative to the open reading frame, thereby suggesting that the P-gp arose by fusion of genes.25 </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>The first structure of a mammalian P-gp was derived from the mouse Mdr3 gene product heterologously expressed in Pichia pastoris yeast in the year 2009.26 The structure of mouse P-gp is almost similar to the bacterial ABC transporter MsbA (3B5W and 3B5X).27ABCB1 gene is expressed as 4,872 bp-long messenger RNA (mRNA),24,25 which encodes P-gp, a single polypeptide chain of 1,280 amino acids. </plain></SENT>
<SENT sid="27" pm="."><plain>It has a molecular weight of 170 kDa and spans ~100 kb. </plain></SENT>
<SENT sid="28" pm="."><plain>Both the N and C termini of the polypeptide chain are cytoplasmic and contain three N-linked glycosylation sites (N91, N94, and N99) of 10–15 kDa in the first extracellular loop.28,29 P-gp consists of two similar halves with &gt;65% amino acid similarity.30 The two halves are separated by a flexible linker region.30 Each half is made up of six transmembrane domains and a cytoplasmic NBD. </plain></SENT>
<SENT sid="29" pm="."><plain>All these 12 domains are located in plasma membrane.30 NBD aids in ATP-dependent efflux of substrates or ions across the cell membrane31–33 (Figure 1). </plain></SENT>
<SENT sid="30" pm="."><plain>Several motifs have also been identified in each of the ATP-binding domains, including the Walker-A, Walker-B, A-loop, H-loop, D-loop, Q-loop, and the signature motif “LSSGQ” consensus sequences.30 All these motifs play an important role in the translocation process, which occurs via ATP binding, hydrolysis, and nucleotide release.34,35 Each ATP-binding site is formed from the Walker A and B motifs of one NBD subunit and the “LSSGQ” signature C motif of the other NBD subunit. </plain></SENT>
<SENT sid="31" pm="."><plain>The P-gp drug-binding pocket is formed by the transmembrane helices of the protein and is located in the cytoplasmic inner membrane leaflet.36 The substrate interacts with P-gp, forming an opening within the inner leaflet of the membrane through Van der Waal’s forces, hydrophobic and hydrogen bonding. </plain></SENT>
<SENT sid="32" pm="."><plain>Then, two molecules of ATP bind at the NBD dimer surface.37 After ATP binding, ATP hydrolysis transfers the substrate into a position to be effluxed from the cell. </plain></SENT>
<SENT sid="33" pm="."><plain>At the time of release of the phosphate from ATP, substrate excretion occurs and ADP is released. </plain></SENT>
<SENT sid="34" pm="."><plain>Hydrolysis and the release of ADP and a phosphate molecule reset the protein, so that the process can start again.38,39 A study has shown that a glycosylation-defective mutant does not show altered drug transport.40 </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>P-gp is widely expressed in the tissues essential in drug disposition such as the intestinal epithelium, adrenal glands, canalicular membrane of the hepatocytes of the liver, kidney proximal tubules, and blood–brain barrier.37,41–44 Major functions of P-gp proteins include the transport of drugs such as colchicine, tacrolimus, and quinidine; chemotherapeutic agents such as etoposide, doxorubicin, taxol, and vinblastine; and various lipids, bile salts, toxic compounds, and peptides for antigen presentation across the membranes. </plain></SENT>
<SENT sid="36" pm="."><plain>Due to its ability to transport substrates out of the cell, it helps in the removal of xenobiotics and other drug metabolites from the cell. </plain></SENT>
<SENT sid="37" pm="."><plain>It also functions as a transporter in the blood–brain barrier.37,45 It is overexpressed in cancer cells, resulting into faster efflux of drugs out of the cells.46 This causes a lower concentration of the drugs within the cell, subsequently reducing the efficacy of the drugs in destroying cancer cells. </plain></SENT>
<SENT sid="38" pm="."><plain>Therefore, P-gp is involved in the process of resistance to anticancer drugs. </plain></SENT>
<SENT sid="39" pm="."><plain>It was reported that the P-gp is the first ABC transporter implicated in MDR. </plain></SENT>
<SENT sid="40" pm="."><plain>In breast cancer treatment, chemotherapeutic drugs such as anthracyclines (doxorubicin and v) and the microtubule-stabilizing taxol are affected by MDR. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="41" pm="."><plain>Genetic variations in ABCB1 gene </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>The ABCB1 gene encoding P-gp is highly polymorphic. </plain></SENT>
<SENT sid="43" pm="."><plain>Till date, ~66 coding single-nucleotide polymorphisms (SNPs) in ABCB1 gene have been identified. </plain></SENT>
<SENT sid="44" pm="."><plain>Out of these, 22 are synonymous and 44 nonsynonymous.47 Several studies have shown that these polymorphisms alter the functional expression of the ABCB1 gene.48,50 The expression, efflux, substrate specificity, and mRNA stability of P-gp are influenced by various SNPs present in ABCB1 gene.51 Some studies have also shown that genetic variations affecting the function and expression of ABCB1 are responsible for resistance to many anticancer drugs and therapeutic failure.2,6,46 Therefore, ABCB1 genetic variations affect the pharmacokinetic profiles of various drugs, leading to changes in drug efficacy and side effects. </plain></SENT>
<SENT sid="45" pm="."><plain>Out of 66 SNPs, three of them in the coding region of ABCB1 gene such as 2677G&gt;T/A (exon 21, rs2032582), 3435C&gt;T (exon 26, rs1045642), and 1236C&gt;T (exon 12, rs1128503) are extensively studied and characterized. </plain></SENT>
<SENT sid="46" pm="."><plain>Studies have shown these polymorphisms to be associated with altered mRNA levels,52 protein folding,53 and drug pharmacokinetics.54 </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>The 2677G&gt;T/A polymorphism is a triallelic variant, and it is found in the wild-type sequence with G at nucleotide 2677 and in the variant sequence with A or T. </plain></SENT>
<SENT sid="48" pm="."><plain>It is located on the intracellular side of P-gp after transmembrane region 10. </plain></SENT>
<SENT sid="49" pm="."><plain>It contains a nonsynonymous amino acid change from Ala at codon 893 to Ser/Thr (Ala893Ser/Thr; ABCB1*10). </plain></SENT>
</text></p><p><text><SENT sid="50" pm="."><plain>The other two polymorphisms – 3435C&gt;T (Ile1145Ile; ABCB1*6) and 1236C&gt;T (Gly412Gly; ABCB1*8) – are synonymous SNPs. </plain></SENT>
<SENT sid="51" pm="."><plain>The 3435C&gt;T is present in exon 26 of the ABCB1 gene, involves a C-to-T transformation, and does not alter the amino acid isoleucine. </plain></SENT>
<SENT sid="52" pm="."><plain>The variant allele frequency of 3435C&gt;T in Asian population differed significantly from the African and Caucasian population.55,56 The frequency distribution of this polymorphism in Chinese and Malay population was found to be similar to the Caucasians, whereas it was different among Indians. </plain></SENT>
<SENT sid="53" pm="."><plain>Among the Thai-Indians, variant allele frequency was found to be 33%.57 Although the 3435C&gt;T is a silent mutation, it has been shown to affect the expression and function of the P-gp in many ways.50 Studies have reported conflicting functional effects of this polymorphism with higher58–61 and lower expression levels of P-gp protein.50,62–64 </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>The synonymous 1236C&gt;T SNP is located on exon 12 and encodes for the TM6 region of the P-gp. </plain></SENT>
<SENT sid="55" pm="."><plain>This region is necessary for substrate binding.30 The polymorphism does not involve an amino acid change at position 412 (Gly). </plain></SENT>
<SENT sid="56" pm="."><plain>It has been shown to affect protein folding due to the use of a rare codon when combined with the 3435C&gt;T polymorphism.51,65 </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>These three SNPs are found to be in strong linkage disequilibrium (LD). </plain></SENT>
<SENT sid="58" pm="."><plain>Higher LD value was found between ABCB1 1236C&gt;T and 2677G&gt;T/A polymorphisms (r2=0.89; D′=0.98), whereas ABCB1 2677G&gt;T/A and 3435C&gt;T (r2=0.65; D′=0.87) and ABCB1 1236C&gt;T and 3435C&gt;T (r2=0.62; D′=0.83) showed lower values.66 Polymorphisms 2677G&gt;T/A and 3435C&gt;T are in strong LD with &gt;90% of Japanese,67 60% of European American,68 and 80% of Germans69 having both of these genetic variants. </plain></SENT>
<SENT sid="59" pm="."><plain>There is a considerable large interethnic difference in the combination of all the three polymorphisms present (also designated as ABCB1*2).59 In Africans, the combination of 1236C–G2677G–C3435T alleles is rare, while 1236T–G2677G–C3435C haplotype is frequent.70 However, the results that have been reported so far are inconsistent and the real functional impact of these three SNPs remains controversial.71 Thus, haplotype-dependent analysis has been taken into consideration in various association studies. </plain></SENT>
</text></p><p><text><SENT sid="60" pm="."><plain>Recently, the 1199G&gt;A (rs2229109) polymorphism in P-gp has also been studied. </plain></SENT>
<SENT sid="61" pm="."><plain>It is a nonsynonymous polymorphism, involving an amino acid change from serine to asparagine at position 400 (Ser400Asn) in the cytoplasmic domain of P-gp. </plain></SENT>
<SENT sid="62" pm="."><plain>It has a reported allelic frequency of ~5.5% in Caucasians.50,59,72 This polymorphism alters the efflux and transepithelial permeability of rhodamine-123. </plain></SENT>
<SENT sid="63" pm="."><plain>Cells with the G1199A variants were more sensitive to vinblastine and vincristine therapies, but no difference in resistance was found for doxorubicin.73 </plain></SENT>
</text></p></sec><SecTag type="METHODS"><sec><title><text><SENT sid="64" pm="."><plain>ABCB1 polymorphisms in breast cancer treatment outcome </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Large interindividual variation exists in breast cancer therapeutic outcomes. </plain></SENT>
<SENT sid="66" pm="."><plain>These outcomes are measured in terms of pathological response to NACT, chemotoxicity, and OS. </plain></SENT>
<SENT sid="67" pm="."><plain>Adverse drug reactions are due to variations in ADME profile of therapeutic drugs. </plain></SENT>
<SENT sid="68" pm="."><plain>As polymorphisms in gene encoding for metabolizing enzymes and drug transporters can affect drug efficacy, toxicity, and survival rate, pharmacogenetics helps in the assessment of individuals predisposed to poor response to NACT, higher risk of chemotherapy-induced toxicity, and OS.1,9–11,14,74–77 </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>As we know, ABCB1 gene is highly polymorphic, and these polymorphisms are found to be correlated with phenotypic variation in P-gp expression levels of various tissues. </plain></SENT>
<SENT sid="70" pm="."><plain>Polymorphisms in ABCB1 gene also contribute substantially to MDR, thus accounting for a wide variation in treatment outcomes of patients with breast cancer to standard doses of drug therapy. </plain></SENT>
<SENT sid="71" pm="."><plain>This review focuses on the clinical significance of polymorphisms in ABCB1 gene with respect to breast cancer treatment outcomes. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec><title><text><SENT sid="72" pm="."><plain>Anthracycline-based treatment outcomes </plain></SENT>
</text></title><sec><title><text><SENT sid="73" pm="."><plain>Response </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>Various studies have demonstrated the influence of ABCB1 polymorphism in breast cancer therapeutic response, but the studies are mainly limited to the three SNPs (1236C&gt;T, 2677G&gt;T/A, and 3435C&gt;T) in ABCB1 gene. </plain></SENT>
<SENT sid="75" pm="."><plain>Among them, 3435C&gt;T is the most studied ABCB1 polymorphism. Table 1 depicts the list of association studies based on anthracycline-based breast cancer response to NACT. </plain></SENT>
</text></p><p><text><SENT sid="76" pm="."><plain>Many studies report that 3435C&gt;T plays a role in response to chemotherapy in patients with locally advanced breast cancer.75 A Chinese study found TT genotype of 3435C&gt;T polymorphism to be associated with worse clinical response when compared with CC genotype (P=0.001). </plain></SENT>
<SENT sid="77" pm="."><plain>In the same study, haplotype analysis also revealed significant association with clinical response.15 Another Chinese study on 148 patients treated with anthracycline-based NACT also observed a significantly enhanced therapeutic response in CT, TT, and CT + TT genotypes of ABCB1 3435C&gt;T polymorphism (P=0.039, P=0.018, and P=0.020, respectively).17 The same Chinese study also found haplotype 3435T–1236T–2677T to be significantly associated with response (P=0.041).17 In addition, they reported that patients with CC genotype had a poor prognosis than those with CT and TT genotypes in ABCB1 3435C&gt;T polymorphism (P=0.043).17 </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>Furthermore, a study on 19 patients treated with preoperative anthracycline-based chemotherapy reported that patients with TT genotype of ABCB1 3435C&gt;T polymorphism showed clinical response, while patients with CT genotype did not show any clinical response.78 Similarly, Cizmarikova et al indicated that the CC genotype in ABCB1 3435C&gt;T polymorphism significantly increased the response rate (P=0.021) in 38 subjects, who were administered with anthracycline-based NACT.16 In addition, a study on 68 patients with advanced breast cancer demonstrated the same association (P=0.029).75 It suggests that ABCB1 polymorphisms, especially ABCB1 3435C&gt;T, have a role in predicting response to NACT. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>However, other studies did not find any role of the polymorphism in treatment response.9,10,16 George et al8 evaluated the effect of 3435C&gt;T polymorphism in 96 patients with locally advanced breast carcinoma but did not find any significant association with response to chemotherapy. </plain></SENT>
<SENT sid="80" pm="."><plain>Another study on 120 patients with stage II or III invasive breast cancer found no correlation of ABCB1 1236C&gt;T and 3435C&gt;T polymorphisms with good response.9 Furthermore, Rodrigues et al1 did not find any association between 3435C&gt;T polymorphisms and response to chemotherapy. </plain></SENT>
<SENT sid="81" pm="."><plain>In another study on 100 patients undergoing 5-flurouracil, epirubicin/adriamycin, cyclophosphamide chemotherapy, investigators observed no association with therapeutic response.10 One more study also showed no association of 2677G&gt;T/A SNP with treatment response in patients with breast cancer.15 </plain></SENT>
</text></p><p><text><SENT sid="82" pm="."><plain>Contradictory reports in the literature regarding the effects of ABCB1 polymorphisms on treatment response in patients with breast cancer can be due to small sample sizes and interethnic variations. </plain></SENT>
<SENT sid="83" pm="."><plain>Therefore, meta-analyses were performed to draw overall conclusions. </plain></SENT>
<SENT sid="84" pm="."><plain>We found three meta-analyses studies related to therapeutic response. </plain></SENT>
<SENT sid="85" pm="."><plain>In one study involving subgroup meta-analysis, significant association of ABCB1 1236C&gt;T polymorphism with therapeutic response in Asian patients with breast cancer under dominant model was seen.79 However, meta-analysis performed on ABCBI 1236C&gt;T (three studies), 2677G&gt;T/A (three studies), and 3435C&gt;T (seven studies) polymorphisms with breast cancer response to NACT found no associations.10 Another meta-analysis including a total of seven studies of 464 patients with advanced breast cancer also revealed lack of association between the ABCB1 3435C&gt;T polymorphisms to the response of chemotherapy. </plain></SENT>
<SENT sid="86" pm="."><plain>The subgroup analysis by ethnicity yielded the same results. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="87" pm="."><plain>Toxicity </plain></SENT>
</text></title><p><text><SENT sid="88" pm="."><plain>Many studies and clinical trials have evaluated the impact of genetic variants in ABCB1 with respect to breast cancer treatment side effects. </plain></SENT>
<SENT sid="89" pm="."><plain>These side effects are recorded in terms of edema, fever, diarrhea, and hematological and gastrointestinal toxicities. </plain></SENT>
<SENT sid="90" pm="."><plain>Most of the studies have focused their research on chemotherapy-induced hematological toxicity, such as anemia, leukopenia, neutropenia, and thrombocytopenia. </plain></SENT>
</text></p><p><text><SENT sid="91" pm="."><plain>In one study, 59 Taiwanese women treated with docetaxel, epirubicin, and cyclophosphamide therapy were genotyped for ABCB1 −41A&gt;G, −145C&gt;G, 1236C&gt;T, 2677G&gt;T/A, and 3435C&gt;T SNPs. </plain></SENT>
<SENT sid="92" pm="."><plain>Side effects in terms of neutropenia, febrile neutropenia, leukopenia, febrile leukopenia, pleural effusion, diarrhea, fever, and edema were recorded in the same study. </plain></SENT>
<SENT sid="93" pm="."><plain>The authors have shown significant association of ABCBI 2677G/G genotype with fever (P=0.024) and febrile neutropenia (P=0.027), while 3435C/C genotype with leukopenia (P=0.057).14 On the contrary, Cizmarikova et al16 found no association of 3435C&gt;T with hematologic toxicities in patients with breast cancer, which were measured in terms of grades 2–4 anemia, leukopenia, neutropenia, and thrombocytopenia. </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>For 1236C&gt;T, few reports are available which correlate genotype with breast cancer chemotoxicity. </plain></SENT>
<SENT sid="95" pm="."><plain>Two studies have demonstrated that variant genotype of ABCBI 1236C&gt;T polymorphism were not associated with drug-induced severe toxicity (grade 3 or 4).9,14 However, a study on 207 North Indian patients with breast cancer reported significant association of 1236C&gt;T with grades 2–4 toxicity and anemia (P=0.049 and P=0.046).10 The same study also evaluated the effect of ABCBI 2677G&gt;T/A and 3435C&gt;T polymorphisms with hematological toxicity but could not find any association.10 </plain></SENT>
</text></p><p><text><SENT sid="96" pm="."><plain>Another study evaluated the impact of 2677G&gt;T/A, 3435C&gt;T, and 1236C&gt;T polymorphisms with hematologic toxicity in 153 Chinese Han patients with breast cancer and reported no association of any of the ABCB1 polymorphisms with grades 3–4 neutropenia.15 Similarly, a recent study determined the influence of pharmacogenetics of ABCB1 (1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T) polymorphisms on toxicity in 230 patients with breast cancer treated with doxorubicin and cyclophosphamide but found no impact on toxicity.12 Only meta-analysis reported till date with chemotoxicity also did not show any association.10 </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>In addition to hematological toxicities, gastrointestinal toxicities are common side effects among patients with breast cancer treated with cyclophosphamide and doxorubicin. </plain></SENT>
<SENT sid="98" pm="."><plain>A clinical trial analyzed 78 SNPs in ABCB1, ABCC1, and ALDH1A1 in 882 patients with breast cancer enrolled in the SWOG Phase III trial S0221 and found none of the ABCB1 polymorphisms to be significantly associated with grades 3–4 hematological as well as gastrointestinal toxicity.80 Table 2 illustrates the studies related to anthracycline-dependent chemotoxicity. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="99" pm="."><plain>Survival </plain></SENT>
</text></title><p><text><SENT sid="100" pm="."><plain>Treatment outcomes in terms of disease-free survival (DFS), progression-free survival (PFS), and recurrence rate are also followed up by few studies, and the influence of ABCB1 polymorphisms with these outcomes has been observed. Table 3 lists various studies in context with anthracycline-dependent survival outcomes. </plain></SENT>
</text></p><p><text><SENT sid="101" pm="."><plain>In a study, Kaplan–Meier survival analysis showed that clinical response and TT genotype of 3435C&gt;T polymorphism were related to DFS (P=0.002 and P=0.049). </plain></SENT>
<SENT sid="102" pm="."><plain>However, this association was weakened after adjustment for potential confounding factors such as the tumor node metastasis (TNM) stage, chemotherapy regimens, and clinical response.15 Recently, a report also found ABCB1 3435C&gt;T polymorphism to be significantly associated with longer OS in 216 patients with breast cancer treated with docetaxel and doxorubicin NACT.76 </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>A study found ABCB1 C3435T variants to have a significant prolonged PFS and OS in patients with triple-negative (estrogen receptor–/progesterone receptor–/human epidermal growth factor receptor 2 [HER2]–) status (P=0.001 and P=0.016, respectively). </plain></SENT>
<SENT sid="104" pm="."><plain>Furthermore, a significant association of ABCB1 2677G&gt;T/A variants was seen with longer OS in patients with HER2-negative status in the same study (P=0.036).17 Similarly, a study on 991 patients found GT genotype of the ABCB1 2677G&gt;T/A to be significantly associated with better breast-cancer-specific survival (hazard ratio: 0.5; P=0.021).81 Another study also found variant A of ABCB1 2677G&gt;T/A to be associated with shorter time to progression and OS in 230 patients with breast cancer treated with doxorubicin and cyclophosphamide.12 Similarly, CC genotype in ABCB1 3435C&gt;T significantly increased the longer time to progression (P=0.049) in 38 subjects.16 In addition, a study on five SNPs in ABCB1 (rs2214102, rs1128503, rs2032582, rs2032583, and rs1045642) gene found significant association of −1 A&gt;G (rs2214102) SNP with PFS in 103 patients with breast cancer (P=0.005).13 </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="METHODS"><sec><title><text><SENT sid="105" pm="."><plain>Taxane-based treatment outcomes </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>Taxanes are important cytotoxic drugs administered to patients with breast cancer along with anthracycline-based chemotherapy. </plain></SENT>
<SENT sid="107" pm="."><plain>Paclitaxel and docetaxel are two taxane drugs. </plain></SENT>
<SENT sid="108" pm="."><plain>Docetaxel is associated with peripheral neuropathy. </plain></SENT>
<SENT sid="109" pm="."><plain>Therefore, variations in genes encoding drug metabolizing and transportation enzymes might be responsible for the differences in docetaxel-dependent peripheral neuropathy. Table 4 summarizes the association studies reported till date, based on taxane-based chemotherapy in breast cancer treatment outcomes. </plain></SENT>
</text></p><p><text><SENT sid="110" pm="."><plain>Chang et al74 evaluated the influence of ABCB1 2677G&gt;T/A and 3435C&gt;T polymorphisms in 113 patients with metastatic breast cancer administered with paclitaxel monotherapy. </plain></SENT>
<SENT sid="111" pm="."><plain>Clinical outcomes in terms of response to chemotherapy, toxicity, OS, and chemoresistance were noticed. </plain></SENT>
<SENT sid="112" pm="."><plain>The authors found that none of the genotype or haplotype was correlated with response to chemotherapy or toxicity. </plain></SENT>
<SENT sid="113" pm="."><plain>However, on applying Cox regression analysis, ABCB1 3435 CT genotype was found to be significantly correlated with shorter OS (P=0.026).74 Furthermore, they showed significant association of ABCB1 2677 GG genotype with chemoresistance to paclitaxel and anthracycline (P=0.04 and P=0.04, respectively).74 A report also found ABCB1 3435C&gt;T polymorphism to be significantly associated with longer OS in 216 patients with breast cancer treated with docetaxel and doxorubicin NACT.76 </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>In a study involving 150 patients with early-staged breast cancer, no association of variant genotypes as well as haplotypes of ABCB1 2677G&gt;T/A, 1236C&gt;T, and 3435C&gt;T polymorphisms was seen with neurotoxicity.82 However, in a study on 218 lymph-node-positive Korean patients with breast cancer, TT genotype of ABCB1 3435C&gt;T SNP showed significantly higher risks of neutropenia when compared with its wild-type genotype (P=0.015).83 In the same study, no association of ABCB1 2677G&gt;T/A and 1236C&gt;T polymorphisms was found.83 </plain></SENT>
</text></p><p><text><SENT sid="115" pm="."><plain>However, Tran et al demonstrated that ABCB1 TT genotype of ABCB1 3435C&gt;T polymorphism had an increased incidence of grade 3 neutropenia when compared with CC genotype.84 Another study showed positive correlation of variant genotypes of ABCB1 2677G&gt;T/A and 3435C&gt;T polymorphisms with paclitaxel-dependent neutropenia.85 </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>A recent study analyzed the effect of genetic variants in ABCB1 −129T&gt;C, 61A&gt;G, 1236C&gt;T, 2677G&gt;T/A, and 3435C&gt;T polymorphisms with pathological response in 101 patients with breast cancer receiving NACT with doxorubicin and docetaxel. </plain></SENT>
<SENT sid="117" pm="."><plain>The authors found ABCB1 3435C&gt;T polymorphism to be associated with pathological good response to chemotherapy (P=0.015).77 </plain></SENT>
</text></p><p><text><SENT sid="118" pm="."><plain>A replication study on 1,303 European patients showed significant association of rs3213619 (ABCB1 −129T&gt;C) with taxane-related sensory neuropathy.86 Recently, a report found ABCB1 3435C&gt;T polymorphism to be significantly associated with increased toxicities of neutropenia and diarrhea in 216 patients with breast cancer treated with docetaxel and doxorubicin NACT.74 </plain></SENT>
</text></p><p><text><SENT sid="119" pm="."><plain>Similarly, another study evaluated the role of these three polymorphisms of ABCB1 in taxane-dependent response to NACT in 58 patients and toxicity in 132 patients. </plain></SENT>
<SENT sid="120" pm="."><plain>The authors performed logistic regression, haplotype, and multidimensional reduction analysis for analyzing the data. </plain></SENT>
<SENT sid="121" pm="."><plain>On performing logistic regression, no association was seen with therapeutic response. </plain></SENT>
<SENT sid="122" pm="."><plain>However, in assessing toxicity, significant association of TT genotype and T allele of ABCB1 2677G&gt;T/A polymorphism was found with “grade 1 or no leukopenia” (P=0.0465 and P=0.048, respectively).11 No significant association was reported with response to both NACT and toxicity on haplotype analysis. </plain></SENT>
<SENT sid="123" pm="."><plain>Higher-order gene–gene interaction was performed by multidimensional reduction analysis, and these ABCB1 polymorphisms were present in combination with other genetic variants affecting breast cancer treatment outcomes. ABCB1 1236C&gt;T polymorphism along with CYP3A5*3 was found to be the best interaction model for treatment response (P=0.024) and grades 2–4 anemia (P=0.004).11 However, ABCB1 2677G&gt;T/A, ABCB1 3435C&gt;T polymorphisms were present in higher-order gene–gene interaction model for dose delay/reduction due to neutropenia (P=0.026).11 Thus, we can say that multi-analytical approaches may provide a better evaluation of pharmacogenetic-based treatment outcomes in patients with breast cancer. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="124" pm="."><plain>Other anticancer therapies </plain></SENT>
</text></title><p><text><SENT sid="125" pm="."><plain>Tamoxifen, an antiestrogen, is given to hormone-receptor-positive premenopausal women with breast cancer. </plain></SENT>
<SENT sid="126" pm="."><plain>This prodrug requires bioactivation by cytochrome P450 enzymes such as CYP2D6 and 3A4 to generate its active metabolite, endoxifen, which stops cancer cell growth by preventing estrogen from binding to its receptor. </plain></SENT>
<SENT sid="127" pm="."><plain>However, less information is available regarding the role of ABCB1 drug transporters in endoxifen disposition and response. </plain></SENT>
<SENT sid="128" pm="."><plain>We found two studies in context with ABCB1 polymorphisms and tamoxifen-dependent treatment outcomes in patients with breast cancer. </plain></SENT>
<SENT sid="129" pm="."><plain>One study investigated the clinical impact of ABCB1 polymorphisms with recurrence risk and metastasis in 95 patients with breast cancer treated with tamoxifen and observed patients with homozygous CC genotypes of ABCB1 C3435T with a shorter time to recurrence (P=0.002).87 Other study on 30 Thai patients with breast cancer also showed similar results. </plain></SENT>
<SENT sid="130" pm="."><plain>In patients treated with tamoxifen adjuvant therapy, CT genotype of ABCB1 3435C&gt;T polymorphism was significantly associated with shorter DFS and five times higher risk of recurrence (P=0.041 and P=0.043).57 It shows that ABCB1 3435C&gt;T might have an impact on recurrence risk. </plain></SENT>
</text></p><p><text><SENT sid="131" pm="."><plain>Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. </plain></SENT>
<SENT sid="132" pm="."><plain>It treats patients with breast cancer with HER2/neu-positive status. </plain></SENT>
<SENT sid="133" pm="."><plain>A study reported that ABCB1 polymorphisms were associated with PFS after first-line trastuzumab chemotherapy in 57 patients with HER2-positive metastatic breast cancer. </plain></SENT>
<SENT sid="134" pm="."><plain>They found T allele carriers in ABCB1 2677G&gt;T/A polymorphism to be associated with longer PFS (P=0.037) and OS (P=0.057). </plain></SENT>
<SENT sid="135" pm="."><plain>However, in patients with ABCB1 3435CC genotype, association with shorter PFS (P=0.039) and OS (P=0.093) was found. </plain></SENT>
<SENT sid="136" pm="."><plain>In combined analysis, PFS was significantly longer in ABCB1 1236CC and/or 2677TT carriers compared with the others (P=0.006).88 </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec><title><text><SENT sid="137" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="138" pm="."><plain>P-gp, encoded by ABCB1 gene being a drug transporter, plays an important role in ADME profile of chemotherapeutic drugs, which are administered in the treatment of breast cancer. </plain></SENT>
<SENT sid="139" pm="."><plain>There are large interindividual variations in therapeutic response and toxicity in breast cancer treatment outcomes. </plain></SENT>
<SENT sid="140" pm="."><plain>Many studies have shown the association of genetic variants in ABCB1 gene with breast cancer treatment outcomes in terms of response to NACT, hematological toxicity, and OS. </plain></SENT>
<SENT sid="141" pm="."><plain>Therefore, ABCB1 gene may be potential candidate in pharmacogenetic evaluation of breast cancer treatment outcomes and optimizing individualized therapy. </plain></SENT>
<SENT sid="142" pm="."><plain>However, the results so far are contrasting, and this inconsistency can be due to small sample-sized studies or interethnic variations. </plain></SENT>
<SENT sid="143" pm="."><plain>Most of the previous studies had evaluated the role of several ABCB1 variants; however, a tagger SNP-based approach that covers most of the common variants in a particular population could be more fruitful. </plain></SENT>
<SENT sid="144" pm="."><plain>In addition, the outcome of breast cancer treatment is determined by not only the ABCB1 polymorphisms but also many other polymorphisms belonging to various metabolizing enzyme pathways. </plain></SENT>
</text></p><p><text><SENT sid="145" pm="."><plain>Future perspective multicenter studies comprising large number of samples along with adjustments for various prognostic factors for pharmacogenetic assessment of ABCB1 polymorphisms are required for evaluating their clinical utility in breast cancer therapy protocols. </plain></SENT>
<SENT sid="146" pm="."><plain>Such type of approach would definitely aid in individualized therapy for breast cancer. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="147" pm="."><plain>The clinical or technical support by Dr Gaurav Agarwal, Dr Punita Lal, Dr Sushma Agrawal, Dr Pankaj Chaturvedi, and Abhishek Kumar Singh from the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, is gratefully acknowledged. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn><p><text><SENT sid="148" pm="."><plain>Disclosure </plain></SENT>
</text></p><p><text><SENT sid="149" pm="."><plain>The authors report no conflicts of interest in this work. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="b1-pgpm-9-047"><text><SENT sid="150" pm="."><plain>1RodriguesFFSantosREMeloMBCorrelation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancerGenet Mol Res20087117718318393221 </plain></SENT>
</text></ref><ref id="b2-pgpm-9-047"><text><SENT sid="151" pm="."><plain>2MizunoNSugiyamaYDrug transporters: their role and importance in the selection and development of new drugsDrug Metab Pharmacokinet20021729310815618657 </plain></SENT>
</text></ref><ref id="b3-pgpm-9-047"><text><SENT sid="152" pm="."><plain>3EvansWEMcLeodHLPharmacogenomics – drug disposition, drug targets, and side effectsN Engl J Med2003348653854912571262 </plain></SENT>
</text></ref><ref id="b4-pgpm-9-047"><text><SENT sid="153" pm="."><plain>4StearnsVDavidsonNEFlockhartDAPharmacogenetics in the treatment of breast cancerPharmacogenomics J20044314315315024382 </plain></SENT>
</text></ref><ref id="b5-pgpm-9-047"><text><SENT sid="154" pm="."><plain>5ZinziLCapparelliECantoreMContinoMLeopoldoMColabufoNASmall and innovative molecules as new strategy to revert MDRFront Oncol20144224478983 </plain></SENT>
</text></ref><ref id="b6-pgpm-9-047"><text><SENT sid="155" pm="."><plain>6BurgerHFoekensJALookMPRNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseClin Cancer Res20039282783612576456 </plain></SENT>
</text></ref><ref id="b7-pgpm-9-047"><text><SENT sid="156" pm="."><plain>7MutohKTsukaharaSMitsuhashiJKatayamaKSugimotoYEstrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cellsCancer Sci200697111198120416925584 </plain></SENT>
</text></ref><ref id="b8-pgpm-9-047"><text><SENT sid="157" pm="."><plain>8GeorgeJDharanipragadaKKrishnamachariSChandrasekaranASamSSSunderEA single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancerClin Breast Cancer20099316116519661039 </plain></SENT>
</text></ref><ref id="b9-pgpm-9-047"><text><SENT sid="158" pm="."><plain>9ZhangBLSunTZhangBNPolymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancerChin Med J (Engl)2011124219920421362365 </plain></SENT>
</text></ref><ref id="b10-pgpm-9-047"><text><SENT sid="159" pm="."><plain>10ChaturvediPTulsyanSAgarwalGInfluence of ABCB1 genetic variants in breast cancer treatment outcomesCancer Epidemiol201337575476123707158 </plain></SENT>
</text></ref><ref id="b11-pgpm-9-047"><text><SENT sid="160" pm="."><plain>11TulsyanSChaturvediPSinghAKAssessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approachGene20145431697524704000 </plain></SENT>
</text></ref><ref id="b12-pgpm-9-047"><text><SENT sid="161" pm="."><plain>12BrayJSluddenJGriffinMJInfluence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamideBr J Cancer201010261003100920179710 </plain></SENT>
</text></ref><ref id="b13-pgpm-9-047"><text><SENT sid="162" pm="."><plain>13VaclavikovaREhrlichovaMHlavataIDetection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosisClin Chem Lab Med201250111999200723093106 </plain></SENT>
</text></ref><ref id="b14-pgpm-9-047"><text><SENT sid="163" pm="."><plain>14TsaiSMLinCYWuSHSide effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphismsClin Chim Acta2009404216016519332043 </plain></SENT>
</text></ref><ref id="b15-pgpm-9-047"><text><SENT sid="164" pm="."><plain>15JiMTangJZhaoJXuBQinJLuJPolymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patientsCancer Biol Ther201213526427122310978 </plain></SENT>
</text></ref><ref id="b16-pgpm-9-047"><text><SENT sid="165" pm="."><plain>16CizmarikovaMWagnerovaMSchonovaLMDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcomePharmacogenomics J2010101626919752884 </plain></SENT>
</text></ref><ref id="b17-pgpm-9-047"><text><SENT sid="166" pm="."><plain>17WuHKangHLiuYRoles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomesJ Cancer Res Clin Oncol201213891449146222526155 </plain></SENT>
</text></ref><ref id="b18-pgpm-9-047"><text><SENT sid="167" pm="."><plain>18LingVMultidrug resistance: molecular mechanisms and clinical relevanceCancer Chemother Pharmacol199740supplS3S89272126 </plain></SENT>
</text></ref><ref id="b19-pgpm-9-047"><text><SENT sid="168" pm="."><plain>19SchinkelAHJonkerJWMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overviewAdv Drug Deliv Rev200355132912535572 </plain></SENT>
</text></ref><ref id="b20-pgpm-9-047"><text><SENT sid="169" pm="."><plain>20JulianoRLLingVA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsBiochim Biophys Acta19764551152162990323 </plain></SENT>
</text></ref><ref id="b21-pgpm-9-047"><text><SENT sid="170" pm="."><plain>21UedaKClarkDPChenCJRoninsonIBGottesmanMMPastanIThe human multidrug resistance (mdr1) gene. </plain></SENT>
<SENT sid="171" pm="."><plain>cDNA cloning and transcription initiationJ Biol Chem198726225055083027054 </plain></SENT>
</text></ref><ref id="b22-pgpm-9-047"><text><SENT sid="172" pm="."><plain>22FojoALeboRShimizuNLocalization of multidrug resistance-associated DNA sequences to human chromosome 7Somat Cell Mol Genet19861244154203016920 </plain></SENT>
</text></ref><ref id="b23-pgpm-9-047"><text><SENT sid="173" pm="."><plain>23RiordanJRDeucharsKKartnerNAlonNTrentJLingVAmplification of P-glycoprotein genes in multidrug-resistant mammalian cell linesNature198531660318178192863759 </plain></SENT>
</text></ref><ref id="b24-pgpm-9-047"><text><SENT sid="174" pm="."><plain>24BodorMKellyEJHoRJCharacterization of the human MDR1 geneAAPS J200571E1E516146331 </plain></SENT>
</text></ref><ref id="b25-pgpm-9-047"><text><SENT sid="175" pm="."><plain>25ChenCJClarkDUedaKPastanIGottesmanMMRoninsonIBGenomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteinsJ Biol Chem199026515065141967175 </plain></SENT>
</text></ref><ref id="b26-pgpm-9-047"><text><SENT sid="176" pm="."><plain>26AllerSGYuJWardAStructure of P-glycoprotein reveals a molecular basis for poly-specific drug bindingScience200932359221718172219325113 </plain></SENT>
</text></ref><ref id="b27-pgpm-9-047"><text><SENT sid="177" pm="."><plain>27WardAReyesCLYuJRothCBChangGFlexibility in the ABC transporter MsbA: alternating access with a twistProc Natl Acad Sci USA200710448190051901018024585 </plain></SENT>
</text></ref><ref id="b28-pgpm-9-047"><text><SENT sid="178" pm="."><plain>28GribarJJRamachandraMHrycynaCADeySAmbudkarSVFunctional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression systemJ Membr Biol2000173320321410667916 </plain></SENT>
</text></ref><ref id="b29-pgpm-9-047"><text><SENT sid="179" pm="."><plain>29ZhangJTLingVStudy of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translationJ Biol Chem19912662718224182321680860 </plain></SENT>
</text></ref><ref id="b30-pgpm-9-047"><text><SENT sid="180" pm="."><plain>30FungKLGottesmanMMA synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein functionBiochim Biophys Acta20091794586087119285158 </plain></SENT>
</text></ref><ref id="b31-pgpm-9-047"><text><SENT sid="181" pm="."><plain>31JonesPMGeorgeAMThe ABC transporter structure and mechanism: perspectives on recent researchCell Mol Life Sci200461668269915052411 </plain></SENT>
</text></ref><ref id="b32-pgpm-9-047"><text><SENT sid="182" pm="."><plain>32BorstPElferinkROMammalian ABC transporters in health and diseaseAnnu Rev Biochem20027153759212045106 </plain></SENT>
</text></ref><ref id="b33-pgpm-9-047"><text><SENT sid="183" pm="."><plain>33AmbudkarSVDeySHrycynaCARamachandraMPastanIGottesmanMMBiochemical, cellular, and pharmacological aspects of the multidrug transporterAnnu Rev Pharmacol Toxicol19993936139810331089 </plain></SENT>
</text></ref><ref id="b34-pgpm-9-047"><text><SENT sid="184" pm="."><plain>34KrishnamurthyPRossDDNakanishiTThe stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with hemeJ Biol Chem200427923242182422515044468 </plain></SENT>
</text></ref><ref id="b35-pgpm-9-047"><text><SENT sid="185" pm="."><plain>35FreletAKleinMInsight in eukaryotic ABC transporter function by mutation analysisFEBS Lett200658041064108416442101 </plain></SENT>
</text></ref><ref id="b36-pgpm-9-047"><text><SENT sid="186" pm="."><plain>36LooTWClarkeDMRecent progress in understanding the mechanism of P-glycoprotein-mediated drug effluxJ Membr Biol2005206317318516456713 </plain></SENT>
</text></ref><ref id="b37-pgpm-9-047"><text><SENT sid="187" pm="."><plain>37SharomFJABC multidrug transporters: structure, function and role in chemoresistancePharmacogenomics20089110512718154452 </plain></SENT>
</text></ref><ref id="b38-pgpm-9-047"><text><SENT sid="188" pm="."><plain>38CallaghanRFordRCKerrIDThe translocation mechanism of P-glycoproteinFEBS Lett200658041056106316380120 </plain></SENT>
</text></ref><ref id="b39-pgpm-9-047"><text><SENT sid="189" pm="."><plain>39HigginsCFMultiple molecular mechanisms for multidrug resistance transportersNature2007446713774975717429392 </plain></SENT>
</text></ref><ref id="b40-pgpm-9-047"><text><SENT sid="190" pm="."><plain>40SchinkelAHKempSDolleMRudenkoGWagenaarEN-glycosylation and deletion mutants of the human MDR1 P-glycoproteinJ Biol Chem199326810747474818096511 </plain></SENT>
</text></ref><ref id="b41-pgpm-9-047"><text><SENT sid="191" pm="."><plain>41BorstPSchinkelAHSmitJJClassical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammalsPharmacol Ther19936022892997912835 </plain></SENT>
</text></ref><ref id="b42-pgpm-9-047"><text><SENT sid="192" pm="."><plain>42Cordon-CardoCO’BrienJPBocciaJCasalsDBertinoJRMelamedMRExpression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissuesJ Histochem Cytochem1990389127712871974900 </plain></SENT>
</text></ref><ref id="b43-pgpm-9-047"><text><SENT sid="193" pm="."><plain>43FojoATUedaKSlamonDJPoplackDGGottesmanMMPastanIExpression of a multidrug-resistance gene in human tumors and tissuesProc Natl Acad Sci U S A19878412652692432605 </plain></SENT>
</text></ref><ref id="b44-pgpm-9-047"><text><SENT sid="194" pm="."><plain>44SugawaraIKataokaIMorishitaYTissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16Cancer Res1988487192619292894894 </plain></SENT>
</text></ref><ref id="b45-pgpm-9-047"><text><SENT sid="195" pm="."><plain>45KwanPBrodieMJPotential role of drug transporters in the pathogenesis of medically intractable epilepsyEpilepsia200546222423515679503 </plain></SENT>
</text></ref><ref id="b46-pgpm-9-047"><text><SENT sid="196" pm="."><plain>46GottesmanMMFojoTBatesSEMultidrug resistance in cancer: role of ATP-dependent transportersNat Rev Cancer200221485811902585 </plain></SENT>
</text></ref><ref id="b47-pgpm-9-047"><text><SENT sid="197" pm="."><plain>47WolfSJBachtiarMWangJSimTSChongSSLeeCGAn update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokineticsPharmacogenomics J201111531532521625253 </plain></SENT>
</text></ref><ref id="b48-pgpm-9-047"><text><SENT sid="198" pm="."><plain>48IeiriITakaneHHirotaTOtsuboKHiguchiSGenetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapyExpert Opin Drug Metab Toxicol20062565167417014387 </plain></SENT>
</text></ref><ref id="b49-pgpm-9-047"><text><SENT sid="199" pm="."><plain>49Human ATP-Binding Cassette Transporters [database on the Internet]Nutrition, Metabolism and Genomics Group, Wageningen UniversityThe NetherlandsAvailable from: <ext-link ext-link-type="uri" xlink:href="http://nutrigene.4t.com/humanabc.htm">http://nutrigene.4t.com/humanabc.htm</ext-link>Accessed February 25, 2016 </plain></SENT>
</text></ref><ref id="b50-pgpm-9-047"><text><SENT sid="200" pm="."><plain>50HoffmeyerSBurkOvon RichterOFunctional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProc Natl Acad Sci USA20009773473347810716719 </plain></SENT>
</text></ref><ref id="b51-pgpm-9-047"><text><SENT sid="201" pm="."><plain>51Kimchi-SarfatyCOhJMKimIWA “silent” polymorphism in the MDR1 gene changes substrate specificityScience2007315581152552817185560 </plain></SENT>
</text></ref><ref id="b52-pgpm-9-047"><text><SENT sid="202" pm="."><plain>52CascorbiIRole of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugsPharmacol Ther2006112245747316766035 </plain></SENT>
</text></ref><ref id="b53-pgpm-9-047"><text><SENT sid="203" pm="."><plain>53SaunaZEKimchi-SarfatyCAmbudkarSVGottesmanMMSilent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancerCancer Res200767209609961217942888 </plain></SENT>
</text></ref><ref id="b54-pgpm-9-047"><text><SENT sid="204" pm="."><plain>54LongoRD’AndreaMSarmientoRGaspariniGPharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumabExpert Opin Investig Drugs201019suppl 1S41S50 </plain></SENT>
</text></ref><ref id="b55-pgpm-9-047"><text><SENT sid="205" pm="."><plain>55BalramCSharmaASivathasanCLeeEJFrequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlatesBr J Clin Pharmacol2003561788312848778 </plain></SENT>
</text></ref><ref id="b56-pgpm-9-047"><text><SENT sid="206" pm="."><plain>56TangKNgoiSMGweePCDistinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populationsPharmacogenetics200212643745012172212 </plain></SENT>
</text></ref><ref id="b57-pgpm-9-047"><text><SENT sid="207" pm="."><plain>57SensornISirachainanEChamnanphonMAssociation of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifenPharmgenomics Pers Med20136939824019753 </plain></SENT>
</text></ref><ref id="b58-pgpm-9-047"><text><SENT sid="208" pm="."><plain>58IllmerTSchulerUSThiedeCMDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patientsCancer Res200262174955496212208746 </plain></SENT>
</text></ref><ref id="b59-pgpm-9-047"><text><SENT sid="209" pm="."><plain>59KimRBLeakeBFChooEFIdentification of functionally variant MDR1 alleles among European Americans and African AmericansClin Pharmacol Ther200170218919911503014 </plain></SENT>
</text></ref><ref id="b60-pgpm-9-047"><text><SENT sid="210" pm="."><plain>60NakamuraTSakaedaTHorinouchiMEffect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjectsClin Pharmacol Ther200271429730311956513 </plain></SENT>
</text></ref><ref id="b61-pgpm-9-047"><text><SENT sid="211" pm="."><plain>61BrinkmannURootsIEichelbaumMPharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapyDrug Discov Today200161683583911495756 </plain></SENT>
</text></ref><ref id="b62-pgpm-9-047"><text><SENT sid="212" pm="."><plain>62SiegsmundMBrinkmannUSchaffelerEAssociation of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumorsJ Am Soc Nephrol20021371847185412089380 </plain></SENT>
</text></ref><ref id="b63-pgpm-9-047"><text><SENT sid="213" pm="."><plain>63WangDJohnsonADPappACKroetzDLSadéeWMultidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C&gt;T affects mRNA stabilityPharmacogenet Genomics2005151069370416141795 </plain></SENT>
</text></ref><ref id="b64-pgpm-9-047"><text><SENT sid="214" pm="."><plain>64HitzlMDrescherSvan der KuipHThe C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsPharmacogenetics200111429329811434506 </plain></SENT>
</text></ref><ref id="b65-pgpm-9-047"><text><SENT sid="215" pm="."><plain>65HungCCChenCCLinCJLiouHHFunctional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugsPharmacogenet Genomics200818539040218408562 </plain></SENT>
</text></ref><ref id="b66-pgpm-9-047"><text><SENT sid="216" pm="."><plain>66LevranOO’HaraKPelesEABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependenceHum Mol Genet200817142219222718424454 </plain></SENT>
</text></ref><ref id="b67-pgpm-9-047"><text><SENT sid="217" pm="."><plain>67TanabeMIeiriINagataNExpression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 geneJ Pharmacol Exp Ther200129731137114311356939 </plain></SENT>
</text></ref><ref id="b68-pgpm-9-047"><text><SENT sid="218" pm="."><plain>68YamashitaMNakamuraTChoDYLeeJDSohWYRotational motion of flowering stalk in Spiranthes sinensis and its machineryBiol Sci Space200115325425511997629 </plain></SENT>
</text></ref><ref id="b69-pgpm-9-047"><text><SENT sid="219" pm="."><plain>69SiegmundWLudwigKGiessmannTThe effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinololClin Pharmacol Ther200272557258312426521 </plain></SENT>
</text></ref><ref id="b70-pgpm-9-047"><text><SENT sid="220" pm="."><plain>70OzawaSSoyamaASaekiMEthnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1Drug Metab Pharmacokinet2004192839515499174 </plain></SENT>
</text></ref><ref id="b71-pgpm-9-047"><text><SENT sid="221" pm="."><plain>71HaufroidVGenetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug dispositionCurr Drug Targets201112563164621039333 </plain></SENT>
</text></ref><ref id="b72-pgpm-9-047"><text><SENT sid="222" pm="."><plain>72CascorbiIGerloffTJohneAFrequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjectsClin Pharmacol Ther200169316917411240981 </plain></SENT>
</text></ref><ref id="b73-pgpm-9-047"><text><SENT sid="223" pm="."><plain>73WoodahlELYangZBuiTShenDDHoRJMultidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoproteinJ Pharmacol Exp Ther200431031199120715100388 </plain></SENT>
</text></ref><ref id="b74-pgpm-9-047"><text><SENT sid="224" pm="."><plain>74ChangHRhaSYJeungHCAssociation of the ABCB1 gene polymorphisms 2677G&gt;T/A and 3435C&gt;T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patientsAnn Oncol200920227227718836089 </plain></SENT>
</text></ref><ref id="b75-pgpm-9-047"><text><SENT sid="225" pm="."><plain>75KafkaASauerGJaegerCPolymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancerInt J Oncol20032251117112112684679 </plain></SENT>
</text></ref><ref id="b76-pgpm-9-047"><text><SENT sid="226" pm="."><plain>76KimHJImSAKeamBABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapyCancer Sci20151061869325410489 </plain></SENT>
</text></ref><ref id="b77-pgpm-9-047"><text><SENT sid="227" pm="."><plain>77LevyPGligorovJAntoineMInfluence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patientsBreast Cancer Res Treat2013139242142823666532 </plain></SENT>
</text></ref><ref id="b78-pgpm-9-047"><text><SENT sid="228" pm="."><plain>78AshariatiAPolymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expressionActa Med Indones200840418719119151448 </plain></SENT>
</text></ref><ref id="b79-pgpm-9-047"><text><SENT sid="229" pm="."><plain>79ZhouZChenQZuoDWangHHuaYCaiZABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysisInt J Clin Exp Med20158126527225784996 </plain></SENT>
</text></ref><ref id="b80-pgpm-9-047"><text><SENT sid="230" pm="."><plain>80YaoSSuchestonLEZhaoHGermline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerPharmacogenomics J201414324124723999597 </plain></SENT>
</text></ref><ref id="b81-pgpm-9-047"><text><SENT sid="231" pm="."><plain>81VulstekeCPfeilAMSchwenkglenksMImpact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxelBreast Cancer Res Treat2014147355757025168315 </plain></SENT>
</text></ref><ref id="b82-pgpm-9-047"><text><SENT sid="232" pm="."><plain>82EckhoffLFeddersenSKnoopASEwertzMBergmannTKDocetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancerActa Oncol201554453053725383449 </plain></SENT>
</text></ref><ref id="b83-pgpm-9-047"><text><SENT sid="233" pm="."><plain>83KimKPAhnJHKimSBProspective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapyCancer Chemother Pharmacol20126951221122722271208 </plain></SENT>
</text></ref><ref id="b84-pgpm-9-047"><text><SENT sid="234" pm="."><plain>84TranAJullienVAlexandreJPharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphismsClin Pharmacol Ther200679657058016765145 </plain></SENT>
</text></ref><ref id="b85-pgpm-9-047"><text><SENT sid="235" pm="."><plain>85SissungTMMrossKSteinbergSMAssociation of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropeniaEur J Cancer200642172893289616950614 </plain></SENT>
</text></ref><ref id="b86-pgpm-9-047"><text><SENT sid="236" pm="."><plain>86AbrahamJEGuoQDorlingLReplication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with PaclitaxelClin Cancer Res20142092466247524599932 </plain></SENT>
</text></ref><ref id="b87-pgpm-9-047"><text><SENT sid="237" pm="."><plain>87TehLKMohamedNISallehMZThe risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1AAPS J2012141525922183189 </plain></SENT>
</text></ref><ref id="b88-pgpm-9-047"><text><SENT sid="238" pm="."><plain>88KimJWKimJHImSAABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapyOncology201283421822722906996 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="f1-pgpm-9-047" position="float"><label>Figure 1</label><caption><p><text><SENT sid="239" pm="."><plain>A. </plain></SENT>
<SENT sid="240" pm="."><plain>Molecular structure of ABCB1 gene: Containing 28 exons and 28 introns; encoding P-gp of 1280 amino acids. </plain></SENT>
<SENT sid="241" pm="."><plain>B. </plain></SENT>
<SENT sid="242" pm="."><plain>Secondary structure of P-gp protein: This has a single polypeptide chain with both the N and C termini located inside the cytoplasmic region while the 12 trans-membrane domains are located inside the plasma membrane. </plain></SENT>
<SENT sid="243" pm="."><plain>It also consists of two nucleotide binding domains (NBD), which act as ATP binding sites. </plain></SENT>
<SENT sid="244" pm="."><plain>The first extracellular loop contains three glycosylation sites. </plain></SENT>
</text></p><p><text><SENT sid="245" pm="."><plain>Abbreviations: mRNA, messenger RNA; NBD, nucleotide-binding domain. </plain></SENT>
</text></p></caption><graphic xlink:href="pgpm-9-047Fig1"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="t1-pgpm-9-047" position="float"><label>Table 1</label><caption><p><text><SENT sid="246" pm="."><plain>Association studies of ABCB1 polymorphisms with anthracycline-based breast cancer response to neo-adjuvant chemotherapy </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>ABCB1 polymorphisms studied </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>Sample size </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Ethnicity </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Association </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>References </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>41 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Brazil </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>Rodrigues et al1 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>96 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>India </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>George et al8 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>1236C&gt;T, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>120 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>Zhang et al9 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>100 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>India </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>Chaturvedi et al10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>153 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>Association with TT genotype of 3435C&gt;T polymorphism </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Ji et al15 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>38 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>Slovakia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>Association with CC genotype of 3435C&gt;T polymorphism </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Cizmarikova et al16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>148 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>Association with CT, TT, CT + TT genotypes of 3435C&gt;T polymorphism and haplotype 3435T–1236T–2677T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Wu et al17 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>68 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>Germany </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>Association with TT genotype of 3435C&gt;T polymorphism </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>Kafka et al75 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>19 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Asia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>Association with TT genotype of 3435C&gt;T polymorphism </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>Ashariati78 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t2-pgpm-9-047" position="float"><label>Table 2</label><caption><p><text><SENT sid="297" pm="."><plain>Association studies of ABCB1 polymorphisms with anthracycline-based chemotoxicity in breast cancer </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>Study endpoints </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>ABCB1 polymorphisms studied </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>Sample size </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>Ethnicity </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>Association </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>References </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>Grades 3–4 hematological toxicity </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>1236C&gt;T, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>120 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>Zhang et al9 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>Grades 2–4 anemia, leukopenia, overall toxicity </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>207 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>India </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>Association of 1236C&gt;T with grades 2–4 toxicity and anemia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>Chaturvedi et al10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>Dose delay, dose reduction, and inability to complete planned course due to leukopenia/neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>229 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>UK </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>Bray et al12 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>Fever, pleural effusion, leukopenia, febrile leukopenia, neutropenia, febrile neutropenia, edema, diarrhea </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>−41A&gt;G, −145C&gt;G, 1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>59 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Taiwan </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>Association of GG genotype of ABCB1 2677G&gt;T/A with fever and febrile neutropenia; association of CC genotype of ABCB1 3435C&gt; T with leukopenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>Tsai et al14 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>Grades 3–4 neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>153 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>Ji et al15 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>Grades 2–4 anemia, leukopenia, neutropenia, thrombocytopenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>111 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>Slovakia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>Cizmarikova et al16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>Grades 3–4 hematological toxicities and grade 3 gastrointestinal toxicities </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>882 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>North American Breast Cancer Intergroup clinical trial </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>Yao et al80 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t3-pgpm-9-047" position="float"><label>Table 3</label><caption><p><text><SENT sid="346" pm="."><plain>Association studies of ABCB1 polymorphisms with anthracycline-based breast cancer survival outcomes </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>Polymorphisms studied in ABCB1 gene </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>Sample size </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>Ethnicity </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Association </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>References </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>230 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>UK </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>Association of variant A of 2677G&gt;T/A shorter TTP and OS with </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>Bray et al12 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>−1 A&gt;G, 1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T, 2685+49T&gt;C </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>103 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>Czech Republic </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>Association of GG genotype of −1 A&gt;G with worse PFS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>Vaclavikova et al13 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>153 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>Association of TT genotype of 3435C&gt;T polymorphism with DFS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>Ji et al15 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>102 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>Slovakia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>Association of CT + TT genotype of 3435C&gt;T with longer TTP </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>Cizmarikova et al16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>148 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>China </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>Association of 3435C&gt;T variants with prolonged PFS and OS in patients with triple-negative status; association of 2677G&gt;T/A variants with longer OS in patients with HER2-negative status </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>Wu et al17 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>2677G&gt;T/A </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>991 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>Belgium </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>Association of GT genotype of 2677G&gt;T/A with BCSS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>Vulsteke et al81 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-pgpm-9-047"><p><bold>Abbreviations:</bold> BCSS, breast-cancer-specific survival; DFS, disease-free survival; HER2, human epidermal growth factor receptor 2; OS, overall survival; PFS, progression-free survival; TTP, time to progression.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t4-pgpm-9-047" position="float"><label>Table 4</label><caption><p><text><SENT sid="382" pm="."><plain>Association studies of ABCB1 polymorphisms with taxane-based breast cancer treatment outcomes </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>Polymorphisms studied in ABCB1 gene </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>Sample size </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>Ethnicity </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>Association </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>Study endpoints </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>Type of taxane </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>References </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>58 (response); 132 (toxicity) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>India </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>Association of variant T of 2677G&gt;T/A with “grade 1 or no leukopenia” </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>Response to chemotherapy, grades 2–4 anemia, leukopenia, overall toxicity </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>Docetaxel and paclitaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>Tulsyan et al11 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>113 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>Korea </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>Association of CT genotype of 3435C&gt;T with shorter OS; association of GG genotype of 2677G&gt;T/A with chemoresistance </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>Response to chemotherapy, grades 3–4 toxicity, OS, chemoresistance </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>Paclitaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>Chang et al74 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>216 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>Korea </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>Association of TT genotype of 3435C&gt;T with higher risks of diarrhea and neutropenia; association of TT genotype of 3435C&gt;T polymorphism with OS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>Diarrhea, nausea, vomiting, stomatitis, neutropenia, febrile neutropenia, thrombocytopenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>Docetaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>Kim et al76 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>−129T&gt;C, 61A&gt;G, 1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>101 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>France </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>Association of CT + CC genotype of 3435C&gt;T with pathological good response to chemotherapy </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>Response to chemotherapy </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>Docetaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>Levy et al77 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>150 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>Denmark </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>No </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>Peripheral neuropathy </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>Docetaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>Eckhoff et al82 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>218 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>Korea </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Association of TT genotype of 3435C&gt;T with increased toxicities of neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>Myalgia, nail changes, edema, hand–foot skin changes, neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>Docetaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>Kim et al83 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>58 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>France </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>Association of TT genotype of 3435C&gt;T with grade 3 neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>Grade 3 neutropenia, febrile neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>Docetaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>Tran et al84 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>26 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>Germany </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>ABCB1 2677G&gt;T/A and 3435C&gt;T polymorphisms with paclitaxel-dependent neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>Neuropathy, neutropenia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Paclitaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>Sissung et al85 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>−129T&gt;C, 61A&gt;G, 1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>1,303 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>Europe </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>Association of CC genotype of −129T&gt;C with taxane-related sensory neuropathy </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>Sensory neuropathy </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>Paclitaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>Abraham et al86 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-pgpm-9-047"><p><bold>Abbreviation:</bold> OS, overall survival.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
